FLT3

ITDoes matter in leukemia

Research output: Contribution to journalArticle

Abstract

FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

Original languageEnglish (US)
Pages (from-to)1738-1752
Number of pages15
JournalLeukemia
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Protein-Tyrosine Kinases
Leukemia
Mutation
Hematopoietic System
Receptor Protein-Tyrosine Kinases
Hematologic Neoplasms
Acute Myeloid Leukemia
Molecular Biology
Immune System
Therapeutics

Keywords

  • AML
  • FLT3
  • ITD
  • Receptor tyrosine kinase
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

FLT3 : ITDoes matter in leukemia. / Levis, Mark J; Small, Donald.

In: Leukemia, Vol. 17, No. 9, 01.09.2003, p. 1738-1752.

Research output: Contribution to journalArticle

Levis, Mark J ; Small, Donald. / FLT3 : ITDoes matter in leukemia. In: Leukemia. 2003 ; Vol. 17, No. 9. pp. 1738-1752.
@article{2e4569d9c0b941828b2f08cd66d6cabe,
title = "FLT3: ITDoes matter in leukemia",
abstract = "FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.",
keywords = "AML, FLT3, ITD, Receptor tyrosine kinase, Tyrosine kinase inhibitor",
author = "Levis, {Mark J} and Donald Small",
year = "2003",
month = "9",
day = "1",
doi = "10.1038/sj.leu.2403099",
language = "English (US)",
volume = "17",
pages = "1738--1752",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - FLT3

T2 - ITDoes matter in leukemia

AU - Levis, Mark J

AU - Small, Donald

PY - 2003/9/1

Y1 - 2003/9/1

N2 - FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

AB - FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

KW - AML

KW - FLT3

KW - ITD

KW - Receptor tyrosine kinase

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0141836914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141836914&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403099

DO - 10.1038/sj.leu.2403099

M3 - Article

VL - 17

SP - 1738

EP - 1752

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -